La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Sansure Biotech Bilan de santé
Santé financière contrôle des critères 4/6
Sansure Biotech has a total shareholder equity of CN¥7.5B and total debt of CN¥399.4M, which brings its debt-to-equity ratio to 5.3%. Its total assets and total liabilities are CN¥8.7B and CN¥1.2B respectively. Sansure Biotech's EBIT is CN¥410.7K making its interest coverage ratio -0. It has cash and short-term investments of CN¥4.9B.
Informations clés
5.3%
Ratio d'endettement
CN¥399.36m
Dette
| Ratio de couverture des intérêts | -0.001x |
| Argent liquide | CN¥4.95b |
| Fonds propres | CN¥7.53b |
| Total du passif | CN¥1.22b |
| Total des actifs | CN¥8.75b |
Mises à jour récentes de la santé financière
Pas de mise à jour
Recent updates
Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital
Jun 03
Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems
May 03Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't
Apr 26Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher
Feb 28Analyse de la situation financière
Passif à court terme: 688289's short term assets (CN¥6.1B) exceed its short term liabilities (CN¥720.9M).
Passif à long terme: 688289's short term assets (CN¥6.1B) exceed its long term liabilities (CN¥495.6M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 688289 has more cash than its total debt.
Réduire la dette: 688289's debt to equity ratio has increased from 0% to 5.3% over the past 5 years.
Couverture de la dette: 688289's debt is not well covered by operating cash flow (9%).
Couverture des intérêts: 688289 earns more interest than it pays, so coverage of interest payments is not a concern.